Skip to main content
. 2016 Oct 26;8(12):899–907. doi: 10.14740/jocmr2773w

Figure 2.

Figure 2

Antithrombotic capacities (AR-AUC (a) and PL-AUC (b)) at trough and peak in blood from patients. †P < 0.05 vs. rivaroxaban at trough. *P < 0.05 vs. trough.